|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
|
5/2004
vol. 3 abstract:
Tibolonw in hormone replacement therapy (part 2)
Artur J. Jakimiuk
,
Jacek Tomaszewski
,
Michał Bogusiewicz
Prz Menopauz 2004; 5: 6-13
Online publish date: 2004/10/22
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Since over 40 years hormone replacement therapy (HRT) is a standard treatment for menopausal symptoms. Quality of life improvement caused by the use of HRT was regarded to be beneficial for bone and cardiovascular system. However, recent studies showed that the prolonged use of HRT may be associated with increased risk of breast cancer. Moreover, HERS and WHI trials changed accepted opinion on use of hormone therapy in the primary and secondary prevention of cardiovascular diseases. Tibolone, a drug acting by a unique mechanism, since 1988 has been widely usded in over 70 countries. This review presents contemporary data on the effect of tibolone on the hot flushes, mood, sexual function and uterus.
keywords:
menopause, hormone replacement therapy, tibolone |